Core Viewpoint - The company reported a significant loss for the mid-2025 period, primarily due to unrealized losses on convertible bond investments, contrasting with a profit in the same period of 2024 [1] Financial Performance - The group recorded revenue of approximately 28 million HKD during the mid-2025 period [1] - Loss from continuing operations amounted to about 459 million HKD, compared to a profit of approximately 102 million HKD in the mid-2024 period [1] - The unrealized loss on convertible bond investments was approximately 443 million HKD, classified as other receivables as of September 30, 2025, which is a non-cash item [1] - In the mid-2024 period, the same investment recorded a fair value gain of about 110 million HKD [1] Industry Outlook - The Chinese pharmaceutical market is expected to achieve healthy growth driven by evolving demand for quality medical services and diversified pharmaceutical supply amid structural transformation led by national healthcare reform policies [1] - Despite facing challenges such as strict regulations and intense competition, the company believes there are potential development opportunities in the expanding consumer base within the Chinese pharmaceutical market [1] - The company plans to continuously monitor market trends and explore potential collaborations with strategic partners to develop pharmaceutical and health-related products, aiming to promote long-term development [1]
精优药业(00858.HK)中期盈转亏至4.59亿港元